Species: | Rabbit |
Applications: | WB IHC IF ICC |
Immunogen Range: | A synthetic peptide |
Clonality: | Polyclonal Antibody |
Isotype: | IgG |
GENE ID: | 673 |
Swiss Prot: | P15056 |
Synonyms: | B-RAF, B-RAF proto-oncogene serine/threonine-protein kinase, B-Raf proto-oncogene serine/threonine-protein kinase, BRAF, BRAF1, EC 2.7.1.37, EC 2.7.11.1, RAFB1, RMIL, RMIL serine/threonine-protein kinase, c-RMIL, kinase B-Raf, p94, v-Raf murine sarcoma vi |
Purification: | Affinity purification |
Storage: | Store at -20°C or -80°C in PBS with 0.02% sodium azide and 50% glycerol. Avoid freeze/thaw cycles. |
Background: | BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1; RAFB1; B-RAF1; FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers. |
Caculated MW: | 62 kDa |
Observed MW: | Refer to Figures |
Applications: |
WB 1:500-1:1000 IHC 1:50-1:200 IF 1:100-1:500 ICC 1:100-1:500 |
Reacitivity: | Human, Mouse |